Paul Singer’s activist hedge fund Elliott Management has its sights set on a new target: Athenahealth, the medical software program, fitness IT, and information analytics firm run by CEO Jonathan Bush, an outspoken evangelist of the virtual health revolution. Elliott took a 9.2% stake in Athenahealth’s final year and is now creating a $one hundred sixty-in-line-with-percentage, $6. Five billion all-coins offer to snap up the employer outright, CNBC reports. That’s a top rate of nearly 30% to Athenahealth’s closing fee on Friday (and Athena shares promptly jumped sixteen i% n Monday buying and selling following reports of the deal). The question now is whether or no longer Bush and his board of administrators are recreations for the M&A.
DIGITAL HEALTH
Color Genomics launches its population health platform. DNA-trying-out organization Color Genomics is expanding its aims. The company announced a brand new population health initiative focused on most cancers and excessive cholesterol risk genomic checks on Monday. “Through this partnership, the Sidney Kimmel Cancer Center at Jefferson Health and Thomas Jefferson University, the University of Chicago, the University of California, San Francisco, and the University of Washington could be capable of offering genetic testing to their sufferers,” Color stated in a press release. The pass is available in an age of booming call for those styles of checks that have come to be especially popular consumer merchandise within the beyond 12 months.
INDICATIONS
A $1.5 million gene therapy? Gene cures that, in effect, therapy or hugely enhance the blood-clotting disease hemophilia (and possibly aren’t too a long way from the marketplace) ought to include astronomical, document-shattering price tags, Leerink analysts argued on Monday in studies notice: “It appears the reputedly impervious million-dollar threshold may be breached with hemophilia gene therapy, that may achieve this even as still creating a price for society with the aid of reducing the cost of thing alternative therapy,” wrote analysts Joseph Schwartz and Dae Gon Ha. If that does come to pass, it’d be any other instance of a milestone biotech innovation accompanied by a milestone charge.
THE BIG PICTURE
Obamacare’s rapid meals calorie labeling rule is, in the end, going into effect. The Food and Drug Administration (FDA) is pushing through a long-delayed Obamacare regulation under Commissioner Scott Gottlieb: A requirement that chain eating places and merchandising machines prominently show calorie statistics. The rule has floundered over the years (it wasn’t even finalized till three years after the health law’s passage); now, a Trump management official is making it a
The Author.
“Steven Schachter is Professor of Neurology at Harvard Medical School; Chief Academic Officer and Director of Neurotechnology for the Center for Integration of Medicine and Innovative Technology, Boston; and Senior Neurologist, Beth Israel Deaconess Medical Center, Boston. Dr. Schachter is Co-Chair of the ILAE Therapeutics Strategies Commission and serves on the ILAE Global Campaign Task Force. He is the Past President of the American Epilepsy Society, Chair of the Professional Advisory Board of the Epilepsy Foundation, and a member of the Epilepsy Foundation Board of Directors.
He has directed over 70studys studies involving antiepileptic treatment plans and published over 200 articles and chapters. He compiled the 6-volume Brainstorm series, allotted to over a hundred and fifty 00 patients and households internationally,a nd edited or wrote 23 different books on epilepsy and conduct. Dr. Schachter is the founding editor and editor-in-chief of Epilepsy & Behavior. “
